At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 861 enrolled
Drug / intervention
Copaxone®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CONFIDENCE: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone(R) (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Jul 16, 2015·Updated Dec 9, 2021
In Brief
A Phase 4 clinical trial evaluating Copaxone® for Multiple Sclerosis. Completed, enrolled 861 participants across 97 sites in 16 countries.
Detailed Summary
The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone 20 mg/mL once daily (QD) group over 6 months of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesArgentina, Austria, Belgium, Croatia, Finland, France, Germany, Ireland, Italy, Mexico, Poland, Puerto Rico, Russia, Spain, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartAug 2015
Primary CompletionJan 2017
Study CompletionJun 2017
TodayJul 2026
First PostedJul 16, 2015
Enrollment StartAug 10, 2015
Primary CompletionJan 10, 2017
Study CompletionJun 2, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.0 years ago
Interventions
Copaxone®drug
Subcutaneous Injections